NCT07406542 2026-02-12
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
Clinical Trials
6 trialsNCT07286162 2026-01-27
CALM-TF
University Health Network, Toronto
Phase 3 Not yet recruiting
NCT07342478 2026-01-16
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
Phase 3 Not yet recruiting
NCT05810623 2023-04-12
MINERVA
Medical University of Vienna
Phase 3 Not yet recruiting
NCT05798819 2023-04-05
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3 Not yet recruiting
NCT05715840 2023-02-08
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting